Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: Results of a two-year, multicentre, non-comparative study

Sakari Reitamo, Jean-Paul Ortonne, Carsten Sand, Jan Bos, Frederic Cambazard, Thomas Bieber, Christian Gronhoj-Larsen, Malcolm Rustin, Regina Folster-Holst, Marie Schuttelaar

Research output: Contribution to JournalArticleAcademicpeer-review

22 Citations (Scopus)


Atopic dermatitis often requires long-term treatment. This European, multicentre, non-comparative, 24-month, follow-up study investigated the efficacy and safety of 0.1% tacrolimus ointment applied to adults with atopic dermatitis. Patients (n=672) applied a thin layer of 0.1% tacrolimus ointment twice daily for 3 weeks to all affected body areas. After 3 weeks, ointment was applied once daily. Clinical improvement became apparent after 2 weeks of treatment and 65.5% of patients had a rating of clearance, excellent or marked improvement by month 3. Skin burning (31.7%) was the most common causally-related adverse event, followed by pruritus (11.3%) folliculitis (6.4%), alcohol intolerance (5.7%), herpes simplex (5.7%), skin infection (4.6%), skin erythema (3.3%) and hyperaesthesia (2.4%). The most commonly reported infections were flu syndrome (12.9%), skin infection (9.8%), folliculitis (7.4%) and herpes simplex (7.0%). Long-term treatment up to 24 months with 0.1% tacrolimus ointment is safe and efficacious in adults with atopic dermatitis
Original languageEnglish
Pages (from-to)406-412
JournalActa dermato-venereologica
Issue number5
Publication statusPublished - 2007

Cite this